A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Trial Profile

A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs AGS 16C3F (Primary) ; Axitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Agensys
  • Most Recent Events

    • 30 Oct 2017 Planned End Date changed from 30 Jun 2018 to 1 Jan 2019.
    • 30 Oct 2017 Planned primary completion date changed from 31 Jan 2018 to 1 Jan 2019.
    • 13 May 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top